Eli Lilly and Company / AurKa Pharma Inc.

Solid Tumors (incl. Small Cell Lung Cancer)

30K US cases/yr

Disease Overview

Small cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer accounting for ~13% of lung cancer diagnoses, with high proliferation rate, early metastasis, and dismal long-term survival despite initial chemo-sensitivity. Aurora kinase A is overexpressed in SCLC and other solid tumors and is implicated in MYC-driven proliferation, making selective Aurora A inhibition a rational targeted approach in tumors that have largely defied precision medicine. Standard of care relies on platinum-etoposide chemotherapy with PD-L1 inhibitors (Tecentriq, Imfinzi) in extensive-stage disease.

Competitive Landscape

Targeted therapy in SCLC has historically been a graveyard—decades of failures with PARP inhibitors, DLL3 ADCs, and rovalpituzumab tesirine (discontinued). The current standard of care is platinum-etoposide plus PD-L1 inhibitor (Roche's Tecentriq, AstraZeneca's Imfinzi), with Amgen's Imdelltra (tarlatamab, DLL3-targeted BiTE) approved 2024 for second-line ES-SCLC. Aurora kinase inhibition has cycled through earlier candidates (Tak-901, alisertib/MLN8237 from Millennium/Takeda, AZD1152), most of which failed on tolerability or modest efficacy in unselected populations. AurKa's AK-01 (LY3295668) was originally discovered at Lilly, divested to TVM Capital's AurKa vehicle in 2016, then reacquired in 2018 as Lilly rebuilt its oncology pipeline under CEO David Ricks—within five days Lilly also announced the $1.6B Armo Biosciences acquisition. The deal restored a 'first-in-class' selective Aurora A inhibitor to Lilly's portfolio at a steep discount versus its later-stage oncology buys, betting on biomarker-defined SCLC and other MYC-amplified tumors as the differentiating wedge against prior pan-Aurora failures. Source: https://www.fiercebiotech.com/biotech/lilly-regains-oncology-asset-up-to-575m-aurka-deal